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ABSTRACT 
With an estimated 34 million people living with HIV in 2011, HIV remains a major 
public health issue (Joint United Nations Programme on HIV/AIDS, 2012). In response, 
researchers are working to develop a range of new prevention technologies (NPTs)—
including microbicides, pre-exposure prophylaxis (PrEP), and vaccines—each of which 
will need to be strategically introduced in order to ensure high levels of uptake and, in 
turn, a significant impact on the HIV epidemic. However, the introduction of prevention 
technologies can prove challenging.  
In the early 1990’s the female condom—the first female-initiated prevention 
technology—offered the hope of lowering HIV and STI infection rates while providing an 
additional contraceptive choice to the millions of women who lacked access to 
contraception (Pathfinder, n.d.). In a few settings the female condom was integrated into 
family planning and other services and enjoyed high levels of acceptance and uptake. In 
most others female condoms were marginalized and never made it into the mainstream. 
Overall, more than 20 years after their initial introduction, female condoms are still not 
used as widely as they should be as a way to prevent HIV and unwanted pregnancy 
and constitute a missed opportunity for the public health field.   
As the HIV prevention field looks toward a generation of new prevention 
technologies, important lessons for their eventual introduction can be garnered from the 
experience of the female condom. By examining female condom success stories, such 
as those from South Africa and Zimbabwe and disappointments, like the introduction of 
female condoms in the United States, program planners can strategically design 
informed introduction efforts, increasing the likelihood they will have a significant public 
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health impact. This paper offers a range of lessons and recommendations for public 
health practitioners seeking to design programs for the introduction of NPTs. Some of 
these lessons include the need to:  
• engage communities and the advocacy community, 
• focus on education and training including that of end users’ sexual partners,   
• carefully select target populations, 
• integrate NPTs into existing health services and programs, 
• ensure strong leadership, 
• negotiate the end cost of products, 
• expand distribution systems, and  
• continually monitor and evaluate programs. 
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GLOSSARY 
 
AIDS: acquired immunodeficiency syndrome 
ARV: antiretroviral  
CE mark: European Conformity mark 
CHANGE: Center for Health and Gender Equity 
FC1: FC1® Female Condom 
FC2: FC2® Female Condom 
FDA: US Food and Drug Administration 
FHC: Female Health Company 
FHF: Female Health Foundation 
GCWA: Global Coalition on Women and AIDS 
HIV: human immunodeficiency virus 
M&E: monitoring and evaluation 
MCC: South Africa Medicines Control Council  
MoH: Ministry of Health 
NGO: nongovernmental organization 
NPT: new prevention technology 
PEPFAR: President’s Emergency Plan for AIDS Relief 
PrEP: pre-exposure prophylaxis 
PSI: Population Services International 
STI: sexually transmitted infection 
UNAIDS: Joint United Nations Programme on HIV/AIDS 
UNFPA: United Nations Population Fund 
UNHCR: Office of the United Nations High Commissioner for Refugees 
UNICEF: United Nations Children’s Fund 
US: United States 
USAID: United States Agency for Development 
WHO: World Health Organization 
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INTRODUCTION 
It is well known that HIV remains as a major global public health issue. In 2011, 
an estimated 34 million people were living with HIV, with 7,400 people becoming newly 
infected every day (Joint United Nations Programme on HIV/AIDS, 2012). Due to a 
combination of factors, including unequal access to education; a greater physiological 
vulnerability; widespread gender based violence; and a limited capacity to negotiate 
sexual decisions, women face greater barriers in preventing and treating HIV and are 
therefore are disproportionately affected by the epidemic (UNAIDS, 2012). In fact, 
young women (ages 15 to 24) are the most at-risk with infection rates twice as high as 
their male counterparts (United Nations Children’s Fund, 2011).  
In response, the last several decades have seen a move toward combination 
prevention strategies, with behavior change, condom promotion, structural 
interventions, biomedical research, and universal treatment efforts each playing their 
part (United Nations Population Fund, World Health Organization & PATH, 2005). In the 
biomedical field, researchers are working to develop a range of new prevention 
technologies (NPTs) including microbicides, pre-exposure prophylaxis (PrEP), and 
vaccines. While male condoms have been in use for centuries, and for more than 80 
years in their current latex form, the fact remains that many people are unable or 
unwilling to use male condoms and a greater range of prevention options is vital 
(Youssef, 1993). If these new technologies are to have any significant public health 
impact, introduction efforts need to be well planned and draw on the lessons learned of 
past introduction efforts.   
In the 1990s, such an introduction effort took place around the female condom. 
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The female condom emerged on the scene as the first female-initiated prevention 
device that could offer protection against HIV, as well as other sexual transmitted 
infections (including those that contribute to HIV vulnerability) and pregnancy. In 
addition, the female condoms offered a range of unique advantages including 
addressing gender inequalities and aiding women who have a difficult time negotiating 
the use of male condoms (Forbes, 2012; Global Coalition on Women and AIDS, n.d.). 
However, despite a few success stories, the initial introduction of the female 
condom constituted a public health intervention failure in many places. In settings where 
the female condom enjoyed success, it was integrated into family planning and health 
services and, in turn, enjoyed high levels of acceptance and uptake. In others, female 
condoms were marginalized and still have not made it into the mainstream. Overall, 
more than 20 years after their initial introduction, female condoms are still not used as 
widely as they should be as a way to prevent HIV and unwanted pregnancy. This 
constitutes a missed opportunity for the public health field.   
As the HIV prevention research field moves toward introduction efforts around a 
potential range of NPTs it is worth exploring the uneven experience of the female 
condom. This paper examines the experience of the female condom in order to draw 
lessons learned for the eventual introduction of other novel HIV prevention 
technologies.    
 
BACKGROUND 
A thin sheath inserted by a woman into her vagina before sex (or inserted anally 
by a man or woman for protection during anal sex), the female condom is the first HIV 
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and STI prevention device designed for a woman to use without her partner’s active 
involvement. While numerous studies have shown that many women will still require 
their partner’s consent to use a female condom and/or will choose to disclose their use 
of the female condom (Hoffman, Mantell, Exner, & Stein, 2004), female condoms 
expand the range of prevention options available and provide a device that women can 
initiate and insert well before sexual intercourse. Further, the female condom remains 
the only HIV prevention alternative to the male condom that offers the extra benefit of 
protection against unwanted pregnancy.  
When first introduced, the female condom offered great hope in the fight against 
HIV. Increasing the number of sex acts that are protected is the key to reducing sexual 
transmission of HIV, and expanding the range of prevention options available is one of 
the most promising ways of achieving greater rates of protection (GCWA, n.d.).  
The history of the female condom and the Female Health Company 
In 1984, just three years after the HIV epidemic was uncovered, Lasse Hessels—
a Danish doctor—invented the female condom (Peters, Jansen, & van Driel, 2010). 
Soon after, Hessels traded the rights to market the female condom in North America to 
the US-based Wisconsin Pharmacal Co., Inc. in exchange for their developing the 
product to meet the US Food and Drug Administration’s (FDA) requirements for 
approval (Frost, Reich & Pratt, 2008).  
Before a drug or medical device can be marketed and distributed in a country it 
must be approved by the recognized regulatory agency. In the United States, this is the 
FDA. In Europe, medical devices are approved with the European Conformity (CE) 
mark while the European Medicines Agency (EMA) evaluates medicines. Some other 
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countries have their own regulatory bodies such as the Indian Drug Authority and the 
South African Medicines Control Council (MCC), while others follow the rulings of some 
of the more established regulatory bodies like the FDA, EMA or MCC.     
With the backing of women’s health advocates, Wisconsin Pharmacal’s new, 
dedicated division, the Female Health Company, finally gained FDA approval for the 
female condom in 1993 (Peters et al., 2010). The uncharacteristically long regulatory 
process was due in part to a change in FDA requirements for medical devices. In 1988, 
“the FDA made a decision to use stricter criteria to evaluate all new condoms…requiring 
more extensive safety and efficacy studies” (Frost, Reich & Pratt, 2008, p.169).  
Meanwhile, faced with financial difficulties and regulatory delays, Hessels sold 
the world rights to the female condom to a Dutch investor who established Chartax 
Resources, Ltd., a London-based company to manufacture the female condom. Chartax 
quickly gained regulatory approval to market the device in a number of countries outside 
North America (Frost, Reich & Pratt, 2008). In 1995, the Female Health Company 
acquired Chartax and with it the exclusive rights to manufacture and market the female 
condom worldwide (Frost, Reich & Pratt, 2008).  
The Female Health Company’s first generation female condom, the FC1 Female 
Condom®, was primarily distributed in areas with populations at high risk for unintended 
pregnancy and sexually transmitted infections (The Gray Sheet, 1993). Representing an 
improved design, the Female Health Company’s second-generation condom, the nitrile 
FC2 Female Condom®, has since replaced the earlier polyurethane FC1.  The FC1 and 
FC2 remain the only FDA approved female condoms and are currently the only female 
condoms available in the United States. In addition, the Female Health Company is the 
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only female condom manufacturer that has had their female condoms approved by the 
World Health Organization’s (WHO) pre-qualification system (Peters et al., 2010). 
Without the backing and approval of the WHO, products are not distributed by United 
Nations agencies like the United Nations Population Fund (UNFPA) or other public 
donors that follow WHO guidelines (Peters et al., 2010). As these agencies and donors 
distribute the bulk of subsidized public health goods worldwide, their support is vital for 
the widespread success of any product. 	  
Today, due to its approval by the FDA and WHO pre-qualification status, the 
Female Health Company’s FC2 Female Condom® is the most widely available female 
condom (Female Health Company, n.d.). It is also the brand of female condom primarily 
used by global health and development agencies and other public donors distributing 
the female condom for free or at a subsidized cost via public health projects and 
research studies. Yet despite its near monopoly on the female condom, the Female 
Health Company is a small company with one dedicated product that has been plagued 
by financial difficulties (Frost, Reich & Pratt, 2008). These difficulties are in part due to 
the low uptake of the female condom and its relatively high price. The company is 
working with partners toward price reduction. Unlike large pharmaceutical companies 
who trade in high grossing drugs and medical devices, the Female Health Company is 
in the business of delivering a public health good. In fact, according to the company, 
their main market is the public health sector, which distributes the FC2® for use in 
prevention and family planning programs at reduced bulk pricing (Female Health 
Company, n.d.). So while the Female Health Company does provide some education 
and training materials to providers and distributors, the main drivers of female condom 
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promotion are the public health and family planning agencies with which the company 
and its foundation partner. 	  
Other female condom products	  
In addition to the FC1 and FC2 Female Condoms®, two additional products have 
emerged on the market—the Cupid® Female Condom and the Woman’s Condom 
(Forbes, 2012). Since neither of these products has yet been approved by the FDA, 
they are exclusively manufactured and sold outside of the US.   	  
The Cupid® Female Condom, another second generation product, is similar to 
one formerly produced by Medtech Products Ltd. and sold under a variety of brand 
names including the Reddy female condom, V-Amour, L’amour, and the VA w.o.w.® 
Feminine Condom (Center for Health and Gender Equity, n.d.; Forbes, 2012). Now 
produced by Cupid, Ltd., the latex Cupid® Female Condom has been approved by the 
Indian Drug Authority and given the European Conformity (CE) mark by European 
regulators, allowing it to be sold throughout the European Union and used by European 
public-sector agencies (Forbes, 2012; Frost, Reich & Pratt, 2008). The Cupid® Female 
Condom is currently being sold in India, Brazil, Portugal and South Africa (Forbes, 
2012).  	  
 The Woman’s Condom, is gathered into a unique geletin capsule for easy 
insertion. The capsule dissolves rapidly (in less that a minute) inside the body allowing 
the condom to expand and line the vagina.  It is manufactured by the Shanghai Dahua 
Medical Apparatus Company, based in China (Forbes, 2012). Approved by European 
and Chinese regulators in 2010 and 2011 respectively, the Woman’s Condom is in its 
early distribution phase in China and South Africa (PATH, n.d.). PATH, a global health 
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organization and the original creator of the Woman’s Condom, is simultaneously 
working to gain pre-qualification approval for the Woman’s Condom from the WHO and 
expand the condom to developing country markets.   	  
Early introduction efforts 
The Female Health Company first introduced the female condom in Switzerland 
in 1992 (Frost, Reich & Pratt, 2008). In 1993, after receiving approval by the FDA, 
European authorities and regulatory agencies in 11 other countries, the Female Health 
Company began selling the female condom and supplying them to public agencies 
(Frost, Reich & Pratt, 2008). Introduction of the product began in a number of markets, 
with varying degrees of success. Since the female condom was a new product, 
completely unfamiliar to the public, program planners set out to generate initial interest 
in it among a range of stakeholders including governments, women’s groups, local and 
international nongovernmental organizations (NGOs), bilateral institutions, and public 
and private funders.  Depending on the anticipated market, planners and the 
manufacturer involved a combination of these actors in a variety of strategies to 
introduce the female condom with the hopes of lowering rates of HIV, STIs and 
unwanted pregnancy (Hoffman et al., 2004). Some of the strategies used included 
social marketing campaigns; provider education and training; and coordination with 
Ministries of Health (MoH) and national family planning and HIV/AIDS planning bodies 
(UNFPA, WHO & PATH, 2005).   
In 1996, the Female Health Company established the Female Health Foundation 
to work alongside UN agencies, NGOs and national governments to promote the female 
condom through various global women’s health projects (Frost, Reich & Pratt, 2008). 
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While the foundation and its partners saw advances in a few countries where the female 
condom was actively promoted, most early introduction efforts achieved little success 
(Frost, Reich & Pratt, 2008). Introduction efforts took many forms; from public and 
commercial distribution to full blown social marketing campaigns. (Hoffman et al., 2004). 
Most, however, consisted of small pilot projects, “characterized by a lack of funding and 
strategic planning to identify a target audience, train providers or do outreach to 
potential users “ (Warren & Philpott, 2003).  
Condom introduction in places like the US and Europe, by their very nature, did 
not include the support from the global health and development communities that was 
part of some of the developing world efforts. Spurred primarily by the Female Health 
Company—a small company facing financial difficulties—female condom introduction in 
the US and other developed world markets was instead characterized by limited 
advertising and promotion and inadequate distribution within the public health systems 
(Hoffman et al., 2004; Frost, Reich & Pratt, 2008). As noted by public health experts 
Susie Hoffman, Joanne Mantell, Theresa Exner and Zena Stein (2004, p. 141), a major 
lesson from the female condom experience, “is that introduction does not mean simply 
putting the female condom on the pharmacy shelf. Rather, it requires proactive, well-
planned strategies.” 
The second wave of introduction efforts 
In response to the uneven success of early introduction efforts, a number of 
initiatives were launched. Beginning in 1999, the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and the Female Health Company joined forces with ministries of 
health and various NGOs to implement female condom promotion programs in 17 
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countries (Warren & Philpott, 2003). In 2005, UNFPA launched the Global Female 
Condom Initiative to scale-up female condom programming in 23 developing countries. 
While both initiatives enjoyed some local success, they have not yet served to 
significantly alter the fate of the female condom. For instance, despite the Global 
Female Condom Initiative’s achievement in nearly doubling the number of female 
condoms distributed in Africa in just three years, they have not been able to help 
countries establish reliable national distribution systems (Peters et al., 2010). Some 
advocates have also criticized UNFPA’s strategy as one that perpetuates the notion that 
the female condom is a niche product, appropriate for only select groups of high-risk 
women instead of a generalizable public health good (Peters et al., 2010). In the end, 
after various introduction efforts in at least 90 countries over the past 21 years, female 
condoms are still not generally accessible in most countries (UNFPA, 2011).  
What acceptability research told us and continues to tell us 
Over the years, many have questioned whether the arguable failure of female 
condom uptake is simply due to the product being inherently unacceptable to women 
and their partners. However, acceptability studies conducted in a wide range of 
countries, and at different points throughout the research cycle, found good initial 
acceptability of the female condom, ranging anywhere from 37 to 96 percent (FHI360, 
2007; NAM, n.d.a). A meta-analysis of over 40 early acceptability studies from a range 
of cultures and settings found the female condom acceptable to, on average, 50 to 70 
percent of women and men surveyed (GCWA, n.d.). 
Among other benefits, women reported feeling more control over their own 
sexual health; a greater ability to negotiate and ensure safer sex; and enhanced sexual 
13	  	  
pleasure for both themselves and their partners (NAM, n.d.a; Population Council & 
Liverpool VCT, Care & Treatment, 2009)  
In one acceptability study, conducted in 1999 in the United States among women 
attending an STI clinic in Alabama, female condoms were initially used (after their 
introduction and promotion) by participants in about half of their protected sex acts (Artz 
et al., 2000). While female condom use declined over the course of the six-month study, 
they were still used in over one-third of all sex acts twelve months after the start of the 
study (Artz et al., 2000; NAM, n.d.a). What’s more, “of the women who used female 
condoms, 75% also used male condoms, showing that female condoms are generally 
used to increase choice and flexibility rather than as a total substitute for male 
condoms” (NAM, n.d.a).  
In another acceptability study conducted in Tanzania, researchers explored 
participants’ intention to use the female condom after a mass-marketing campaign. In 
the study, women reported that they were highly likely to use female condoms in casual 
situations but less likely to use them with regular partners, and unlikely to use them with 
their husbands (NAM, n.d.a). Male partners, by contrast, said they were likely to us 
female condoms with their wives or regular partners but much less likely to use them 
with casual partners (NAM, n.d.a). 
 Studies conducted by the WHO, the Female Health Company, Population 
Services International (PSI), FHI 360 (then Family Health International), and the 
International Planned Parenthood Federation found that women reported improved 
communication with their partners when they introduced female condoms into their 
stable relationships (GCWA, n.d.). 
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What this tells us is that men and women, in a range of settings, generally find 
the female condom acceptable and, in many instances, have discovered unique 
benefits to its use. Moreover, while some concern has been expressed over the years 
that promotion of female condoms—or any other NPT—would result in male condom 
migration (i.e., a decrease in the number of male condoms used), the introduction of 
female condoms has been shown to increase the number of overall protected sex 
acts—the key to reducing sexual transmission of HIV. In fact, as Hoffman, Mantell, 
Exner and Stein (2004, p. 141) observe: 
“The potential of the female condom does not depend on its being the method of choice 
for the majority of women, or on its being more popular than the male condom. Decades 
of contraceptive research show that expanding the range of options increases the 
likelihood that each woman will find an acceptable method.”  
But the question remains, if user preference is not the reason for female 
condom’s lack of popularity, what is? According to Peters, Jansen and van Driel (2010, 
p. 121), “acceptability may be determined as much by how the technology is introduced 
as by its physical characteristics.”  
 
FACTORS ASSOCIATED WITH LIMITED UTILIZATION  
A range of factors have thwarted attempts at promoting female condoms and sustaining 
their use. The following have all been cited as the basis for the female condom’s 
continued struggle:  
• high cost;  
• regular stock outs;  
• the lack of reliable distribution systems;  
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• provider bias and deficient training;  
• negative perceptions on the part of funders and policy-makers; and  
• the consequent lack of investment in early introduction efforts–particularly the 
failure to invest as much in programming to build familiarity, trust and 
acceptance of the new product as in the purchasing of the condoms, 
themselves.  
Each of these, to varying degrees, contributed to lack of uptake. 
High cost 
Cost is often cited as the chief barrier to scale-up. At introduction, the worldwide 
retail price of the female condom ranged from US $2-3 per condom (Frost, Reich & 
Pratt, 2008; Peters et al., 2010). By contrast, the average retail cost of a male condom 
is US $0.03 (UNAIDS Inter-Agency Task Team on Gender and HIV/AIDS; n.d.).  The 
bulk pricing for female condoms (i.e., the price paid by UNFPA and other public donors) 
is almost 30 times higher than the bulk price for male condoms (Peters et al., 2010). 
From both a consumer and public health programming perspective, this puts female 
condoms at a grave disadvantage.  
Wider distribution and demand, along with increased competition (as additional 
female condom models enter the market) should lower the overall cost (Forbes, 2012).   
The FHC currently has a monopoly on female condom sales in the US (as no 
other product yet has FDA approval) and a virtual monopoly in most other markets, as it 
is producing the vast majority of female condoms used globally.  This has somewhat 
stalled the tendency of market forces to bring prices down as demand goes up.  As 
Peters et al. (2010, p. 125) note:  
“…the cost of the female condom has been caught in a vicious circle – perceived low 
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demand, perceived low acceptability, unwillingness of public policymakers to invest in 
female condom production, purchase and programmes, stock-outs, high prices and 
frustrated demand. The result is a stalemate.”   
It appears that this stalemate can only be broken by WHO’s pre-qualification 
approval of additional brands (which is expected to occur within the next two years) and 
active promotion of female condoms to drive up demand for them. 
Meanwhile, in response to the high cost, some women have turned to reusing 
female condoms to make them more affordable. While the WHO does not recommend 
the reuse of female condoms due to concerns that reuse could weaken the condoms, it 
did publish a draft protocol in 2002 that includes guidance for reuse based on studies 
showing the safety of reuse (Guttmacher Institute, 2001; WHO, 2002). Further studies 
and official guidelines for the safe reuse of female condoms could help to lower the cost 
and increase accessibility.  
Stock outs and the lack of reliable distribution systems 
In many places, the availability of female condoms is often uncertain and 
unreliable. Whether demand is needed to drive the creation of an affordable supply (or 
an increasingly affordable supply) of products that will drive increased demand, the fact 
remains that female condoms currently constitute just over one percent of all condoms 
distributed worldwide (Forbes, 2012). In 2009, only one female condom was available 
for every 36 women (Forbes, 2012; UNFPA, 2011). While this is fueled in part by the 
high cost of female condoms, it is also compounded by the obstacle course created by 
unreliable or ill-conceived distribution systems (Warren & Philpott, 2003) and the 
frequent failure of governments and other funders to recognize that male and female 
condoms are not interchangeable (a mistake that leads them to favor purchasing male 
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condoms as the cheaper alternative).  This misperception misses the unique benefit that 
female condoms provide to women – an increased ability and opportunity to instigate 
condom use.   
Lack of investment and institutional support 
Twenty years after their initial introduction, female condoms still do not enjoy a 
place on the WHO’s essential medicines list. The essential medicines list serves as a 
guide for national and institutional lists of those medicines required for the successful 
functioning of a health system and that address the priority health care needs of the 
population (WHO, n.d., “Access, quality and rational Use,” para. 2). 
“Lists of Essential Medicines also guide the procurement and supply of medicines in the 
public sector, schemes that reimburse medicine costs, medicine donations, and local 
medicine production. Many international organizations, including UNICEF, UNHCR and 
UNFPA as well as nongovernmental organizations and international non-profit supply 
agencies, have adopted the essential medicines concept and base their medicine supply 
system mainly on the Model List.“ 
Female condoms have also received mixed support from international donors. 
For instance, neither the United States Office of the Global AIDS Coordinator nor the 
United States Agency for International Development (USAID) directly funds female 
condom programming. While USAID in-country missions are able to receive technical 
assistance and support for female condom programs through the President’s 
Emergency Plan for AIDS Relief (PEPFAR), missions have to proactively request the 
support (CHANGE, 2011). The failure of the US government to demonstrate institutional 
leadership for the female condom has compounded the lack of on-the-ground support 
by donors and public health programmers. Countless stories abound of USAID missions 
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failing to back female condom programming and promotion efforts, going so far as citing 
a lack of civil society demand for female condoms, even when advocacy groups are 
beseeching them to support female condom expansion (CHANGE, 2011). Apart from 
overarching bias and negative perceptions around the female condom, this 
phenomenon is in large part due to the missions’ insufficient engagement with civil 
society groups in-country (CHANGE, 2011).  
Provider bias and deficient training 
The lack of support for, and promotion of, female condoms among healthcare 
providers has been reported in several studies and anecdotal reports, across various 
locations (Peters et al., 2010). Particularly in low-resource settings, some providers lack 
the training to educate their patients appropriately about female condoms. Some lack 
supplies (e.g. pelvic models) to demonstrate use, and others express concerns about 
stock outs and the inconsistency of supply (Peters et al., 2010). But these are not the 
only barriers. Some health providers are biased against the female condoms or are 
inhibited about discussing sex explicitly with their patients, and consequently are 
uncomfortable initiating discussion of women’s HIV prevention options. (Peters et al., 
2010). With proper education and training, providers can overcome personal biases 
and/or limitations and develop the capacity to properly educate and encourage their 
clients to try new HIV prevention tools.  
Negative perceptions  
Since its introduction, the female condom has been plagued by an onslaught of 
negative attitudes and perceptions. At best, there is a persistent myth (debunked to 
some degree by acceptability research) that women do not accept nor do they like 
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female condoms (Peters et al., 2010). At worst, female condoms are presented in some 
settings as a tool of promiscuity or a joke (Kaler, 2004a). The female condom has been 
dismissed as weird-looking, noisy, or irrelevant because (some argue) women have little 
say over what happens with their bodies and that dynamic is immutable (Peters et al., 
2010).  
Some of these negative perceptions arose from the inadequate ways in which 
female condoms were initially introduced and (in some places) continue to be 
programmed. In some settings, they were “targeted only at sex workers in the belief that 
only sex workers can take protection into their own hands. Targeting sex workers might 
have led to stigmatisation rather than normalisation of the product” (Peters et al., 2010, 
p. 122). In some areas, due to the challenge female condoms pose to traditional gender 
norms, they have become associated with promiscuity and infidelity (Feldblum, 2001).  
The media in particular has played a role in fueling negative attitudes around the 
female condom, but so too have international public health experts by their blatant 
failure to give adequate attention and space to such a promising prevention technology 
(Kaler, 2004a; Peters et al., 2010).   
Failure of early introduction efforts 
Generally speaking, early female condom introduction efforts failed to identify 
target audiences carefully, train providers adequately, or engage in outreach to potential 
users (Warren & Philpott, 2003). Such efforts were typically undertaken without either 
adequate funding or strategic planning and handled as “procurement exercises” in 
which available resources were used to purchase and distribute female condoms at 
random (Warren & Philpott, 2003, p. 131). Most failed to draw on best practices for 
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introducing a new product into an existing method-mix, such as the inclusion of 
hierarchical counseling and outreach to men (NAM, n.d.a). While the female condom is 
designed as a female initiated method, the reality is most women do not hide it from 
their partner(s) and male cooperation is necessary (Hoffman et al., 2004). Involving men 
not only supports effective product use (e.g. so that penile insertion into the condom, 
not around the condom, is assured), it also enhances the likelihood of couples 
communicating more easily about sex and negotiated protection. But little attention has 
been paid in most settings to the need to direct information to male partners and 
encourage open communication between partners about protection (Frost, Reich & 
Pratt, 2008).  
Each of these factors—regular stock outs, unreliable distribution, a lack of 
provider training, high-cost, provider bias, negative perceptions and lack of 
investment—are not independent of one another. Instead, these factors interact, 
collectively fueling the failure of female condom uptake. The common thread, with the 
possible exception of its high-cost, is that most of the factors the female condom faces 
are a direct result of the failures of its early introduction.    
 
CASE STUDIES: THE SUCCESS AND FAILURE OF FEMALE CONDOM 
PROMOTION 
Over the past 20 odd years, the female condom has been introduced throughout 
the developed and developing worlds. Today, according to UNFPA (2011, p. 12), “the 
female condom is available in more than 90 countries through public health 
programmes and is commercially marketed to consumers in ten of those countries.” 
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While the context and experience of each differs, most countries have not achieved 
widespread use of the female condom. This experience is not unique to the developed 
or developing world. Rather, while a handful of countries can be held up as success 
stories, the majority of female condom introduction efforts have, effectively failed. For a 
more in-depth examination of how introduction efforts can lead to a NPT’s success or 
failure, we turn to three individual cases spanning both developing countries and the 
developed world: South Africa, Zimbabwe and the United States.  
South Africa 
South Africa is often heralded as a major example of a female condom success story. It 
is also (not coincidentally) one of the few countries in the world where a national family 
planning program played a central role in introducing female condoms (FHI360, 2007; 
Peters et al., 2010). Developed over the course of three years, South Africa’s 
introduction strategy was crafted jointly by the National Department of Health, the 
Reproductive Health Research Unit, and government staff in each of the country’s nine 
provinces (FHI360, 2007; Warren & Philpott, 2003). The project’s aim was to integrate 
female condoms into the country’s reproductive health program, as well as its HIV/AIDS 
program (Warren & Philpott, 2003). Additional partners included FHI360, the Female 
Health Company and Foundation, UNFPA and the South African National Department 
of Health. These groups worked together to manufacture and purchase the female 
condom, distribute them in-country and provide the technical support and training 
necessary for successful introduction and sustained use.  
 This multi-sectoral collaboration was key to the success of its program (FHI360, 
2007; Peters et al., 2010). Additional support was provided by various social marketing 
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organizations—namely PSI and the Society for Family Planning—that advertised and 
distributed female condoms through pharmacies and other commercial outlets (Peters 
et al., 2010; Warren & Philpott, 2003).  
With the intention of both promoting female condoms to a wide audience and 
avoiding stigmatization, the product was first introduced in 1998 through family planning 
clinics and community based programs (instead of directly to high-risk groups) (Warren 
& Philpott, 2003). Introduction programs were characterized by provider training and 
train-the-trainer efforts that covered a range of contraceptive and STI prevention 
methods as well as communication, counseling, and the teaching of negotiation skills 
(FHI 360, 2007; Warren & Philpott, 2003). As a compliment, program planners 
conducted outreach—including workplace outreach—to target high-risk populations who 
do not typically attend the traditional health services where female condom programs 
were being launched (Warren & Philpott, 2003).   
After the initial period of introduction, concentrated at 31 pilot sites, South Africa 
expanded public distribution and promotion of the female condom. By 2005, its female 
condom program was operating from 204 sites including additional public health clinics, 
workplaces, truck stops, brothels, and universities (FHI360, 2007; Warren & Philpott, 
2003).  
Perhaps the most impressive element of South Africa’s female condom program 
has been their evaluation of early stages, prior to expansion. In 1998 and 2000, before 
expansion of the program, a study was conducted to assess user and provider opinions 
of female condoms, patterns of use, and potential barriers to integration (FHI360, 2007; 
Warren & Philpott, 2003). The study found that female condoms complemented male 
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condom use, that women felt more empowered, and that providers were 
overwhelmingly supportive of female condom integration (FHI360, 2007; Warren & 
Philpott, 2003). Some barriers to integration were also uncovered. The most notable of 
these barriers were a lack of time to counsel and demonstrate use, inadequate 
inventory management and shipping delays, and a suspension of distribution when 
responsible staff were absent (FHI360, 2007). Female condom planners used these 
findings to inform the expansion of their promotion and distribution efforts.  
South Africa’s female condom program is marked by its strong national 
leadership, early and comprehensive provider training, proactive introduction strategy, 
and early stage evaluation efforts conducted prior to program expansion. Further, by 
partnering with family planning services, the program was able to minimize stigma and 
optimize limited resources while building a program that could be sustained long-term 
(Warren & Philpott, 2003). 
Zimbabwe 
Local advocacy played a key role in the successful introduction of female 
condoms in Zimbabwe (Meekers, 1999; Warren & Philpott, 2003). Faced with rising 
rates of HIV, particularly among women, HIV and women’s health activists began 
organizing discussions of women in order to encourage them to protect themselves 
(Ray et al., 1995). Discouraged by what seemed to be the impossibility of negotiating 
male condom use with their partners, those involved saw female condom as a source of 
new hope for women in Zimbabwe (Ray et al., 1995). Similar to many places, male 
condoms are highly stigmatized in Zimbabwe. Seen as the mark of promiscuity and 
mistrust or an admission of HIV infection, condoms are most often used in casual 
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relationships and/or with commercial sex workers (Warren & Philpott, 2003). Female 
condoms offered an alternative—a new method free from any legacy of stigma. 
In 1996, women’s health activists, led by the Women and AIDS Support Network, 
organized a public march to petition the MoH and the National AIDS Control 
Programme to make the female condom widely available (Meekers, 1999; Peters et al., 
2010). They were successful in garnering government support and regulatory agency 
approval. In 1997, Zimbabwe launched what is now held up as an example of a 
successful female condom program (Kerrigan et al., 2000; Warren & Philpott, 2003). As 
in South Africa, this success is generally attributed to the collaboration between a range 
of public and private stakeholders and the strategic implementation of a comprehensive 
program to introduce female condoms into the public health sector (Hoffman, et al. 
2004; Peters et al., 2010). Among other benefits, strong leadership from the MoH 
helped to ensure inclusion of the female condom in the National AIDS Control 
Programme and budget, prerequisites for continued funding and access  (Warren & 
Philpott, 2003). In at least one post-marketing survey, more than half of the female 
condom users surveyed indicated they had heard of the device from a health provider, 
highlighting Zimbabwe’s success in provider outreach and training, including training for 
pharmacists and community based organizations (Hoffman et al., 2004; Kerrigan et al., 
2000).  
Given the high levels of stigma attached to the male condom in Zimbabwe, 
program planners—most notably PSI—commercially marketed the female condom 
primarily to married women as a contraceptive sheath under the brand name Care™ to 
draw attention to its capacity for contraception, rather than disease prevention (Warren 
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& Philpott, 2003). The condoms were sold at clinics, pharmacies and other commercial 
outlets at a heavily subsidized price of US$0.24 (Kerrigan et al., 2000). At the same 
time, the government launched a public sector female condom program to reach rural 
and high-risk communities (Warren & Philpott, 2003).  
Early evaluation efforts made it possible for Zimbabwe’s female condom program 
to be continuously adapt based on feedback received from users and providers, 
ensuring the continued relevance of its promotion efforts (Warren & Philpott, 2003). 
Approximately one year into Zimbabwe’s female condom introduction program, PSI and 
the Horizons Project conducted a cross-sectional study of female condom users, male 
condom users and those not using either method in order to better understand the 
dynamics of female condom use and strengthen Zimbabwe’s female condom program 
(Kerrigan et al., 2000). Likewise, UNFPA’s later efforts were informed by evaluations of 
past programs and potential barriers to use (UNFPA, 2011).  
Alongside the government’s efforts, women’s health and HIV groups organized 
education programs, furthering female condom promotion across the country (Peters et 
al., 2010). Using a comprehensive social marketing strategy and the public health 
practice of using community-based distributors for health services, female condom 
programmers in Zimbabwe also tapped into existing social structures and norms, 
training 2,070 hairdressers and barbers to act as female condom educators and 
distributors (Bertrand, Pineda, Santiso & Hearn, 1980; UNFPA, n.d.; UNFPA 2011). In 
addition, well-crafted social marketing campaigns that utilized TV, radio and billboards, 
helped to escalate female condom distribution in both the public and private sectors, 
increasing its uptake from an estimated 1.3 million condoms in 2005 to more than 5 
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million in 2008 (UNFPA, 2011). This success also resulted in a drop in female condom 
pricing (CHANGE, 2011). When the female condom was first marketed in Zimbabwe the 
unit cost was US $4.50 (CHANGE, 2011). However, as Zimbabwe expanded its 
program and demand increased, the price dropped to under US $1 (CHANGE, 2011).    
Advocacy, social marketing, and community-based outreach are the hallmarks of 
Zimbabwe’s female condom story. Government leadership and a commitment to 
implementing, monitoring, and evaluating a proactive strategy that integrated female 
condoms into existing services worked to ensure its success (Hoffman et al., 2004).  
United States 
 After its initial introduction in Europe in 1992 and FDA approval in 1993, 
the female condom was first introduced in the United States in the mid-1990s. Faced 
with limited capacity and resources, the Female Health Company had to make choices 
about where to focus its efforts. The company concentrated its efforts toward promoting 
and distributing the female condom in the developing world through their partnerships 
with the public health sector (Female Health Company, n.d.). While social marketing 
campaigns are routinely used to introduce new public health interventions, the Female 
Health Company wrongly assumed that if the female condom was simply made 
available—without social marketing efforts—Western women would readily use it. Under 
this logic the manufacturer simply put the female condom on drug store and clinic 
shelves in much of North America and Europe with little, if any, intentional effort to 
introduce the product (Peters et al., 2010). What US consumers saw was a completely 
unfamiliar device with a high price tag and no complementary programming explaining 
its potential benefits.  
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As a result, unlike its counterparts in South Africa and Zimbabwe, US 
introduction was characterized by inadequate provider training, limited distribution within 
the public health system, inadequate advertisement and promotion and, perhaps most 
notably, ridicule of the female condom in the press (Hoffman et al., 2004). As Amy Kaler 
(2004a, p.142-43) recalls in The Female Condom in North America: Selling the 
Technology of ‘Empowerment’:        
“It was constructed as a ridiculous device, a ludicrous insult to the sensibilities of any 
woman foolish enough to use it…Negative press reports ridiculed the female condom 
comparing it to, among others, a jellyfish, a windsock, a fire hose, a colostomy bag, a 
Baggie, gumboots, a concertina, a plastic freezer bag, something to line Boston’s Inner 
Harbor with…Even writers who acknowledged the female condom a possible means of 
empowering women claimed that it would be doomed by its weirdness.” 
Not surprisingly, the female condom—sold initially under the brand name 
“Reality”—did not enjoy success in the US market. Six years after its initial introduction 
less than one percent of American contraception users were using female condoms 
(Kaler, 2004a). While the method appealed to women’s health advocates and found 
some distribution success in programs responding to poverty and addiction among 
women, the device never seemed to find traction among the mainstream (Kaler, 2004a). 
Without active promotion, provider training or strategies on how to best target US 
consumers, the negative press doomed the female condom to years of mocking and 
limited use.    
Unfortunately, the US experience has been echoed throughout much of the world 
with either negative perceptions or ignorance of the female condom being the product’s 
main trademarks. In the only study conducted in Italy on female condom use and 
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preference, only one fourth of the 162 men and women participating in the study had 
ever heard of the female condom (Spizzichino et al., 2007). In Kenya, while female 
condoms are officially part of the country’s HIV and family planning programs, “women 
have shown little interest [and] overall the demand is low due to general unavailability 
and [lack of] information” (PlusNews, 2011).   
However, thanks to renewed energy and efforts on the part of HIV and women’s 
health advocates, the improved design of the FC2, and increased involvement from the 
Female Health Company, the female condom is starting to gain some ground in the US 
and other markets. In recent years the Female Health Company has begun creating 
public-private partnerships to promote the female condom in key cities throughout the 
US (Frank, 2012). In Washington, DC—the city with the highest HIV prevalence in the 
country—the Female Health Company has partnered with the D.C. Female Condom 
Initiative, a coalition that includes the district’s health department and various 
community based organizations. Based on lessons learned from introduction efforts in 
Zimbabwe, the DC campaign focuses primarily on education and training including the 
use of peer educators (Frank, 2012). In other major cities, with the help of the Female 
Health Company, health departments and advocacy groups have begun efforts to 
increase awareness and uptake of the female condom, sponsoring education seminars 
for health educators and launching awareness campaigns (NAM, n.d.b). US female 
condom advocates are also getting help from another source—African HIV prevention 
advocates and coordinators from countries such as Malawi who have begun travelling 
to the US to help educate American providers in female condom promotion and use 
(NAM, n.d.b).   
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However, despite these renewed efforts, female condoms remain unaffordable 
for many potential users, are difficult to access in some areas, and are continuously 
challenged and under-promoted due to provider bias and negative perceptions.  What’s 
more, while the United States case study offers a striking contrast to the experiences of 
South Africa and Zimbabwe, it is much more representative of the overall female 
condom experience. Whereas Brazil, Ghana, India, South Africa and Zimbabwe are 
often heralded as examples of female condom success, the reality is female condom 
introduction efforts have not resulted in high uptake of the device in the majority of 
markets (Frost, Reich & Pratt, 2008; Peters et al., 2010; Peterson et al., 2008). With the 
bulk of female condoms being distributed by public health and family planning agencies 
throughout the developing world—most notably Africa—traditional commercial sales 
and national public distribution efforts outside those agencies’ priority areas have 
generally suffered (Peterson et al., 2008).  
 
LESSONS LEARNED 
While the majority of efforts around introducing, promoting and sustaining interest 
in the female condom have fallen short, the few success stories offer important insights 
on how program planners can better prepare for future introduction efforts around new 
prevention technologies. According to Warren and Phlipott (2003, p. 130), in addition to 
strong leadership and the involvement of a range of stakeholders, female condom 
successes, “have several key similarities: a focus on training for providers and peer 
educators, face-to-face communication with potential users to equip them with 
information and skills, an identified target audience, a consistent supply, a long 
30	  	  
assessment period to gauge actual use beyond the initial novelty phase, and a mix of 
public and private sector distribution.” 
While there is much to be learned from successful cases like South Africa and 
Zimbabwe, we can draw equally important lessons from the common barriers to access 
and use that characterized much of the female condom’s early introduction, and the 
disappointing experiences of places like the US.  
From an assessment of the early introduction efforts around the female condom 
and the key case studies of South Africa, Zimbabwe and the United States, the HIV 
prevention field should consider the following lessons as they move toward the 
introduction of a range of new prevention technologies.  
Strategically plan and design introduction programs 
Proactive strategies that employ a comprehensive approach, are informed by the 
local context, and identify the best way(s) to position a NPT are crucial for their 
successful introduction and sustained use. In order to plan strategically, UNAIDS and 
WHO (2000) recommend considering the following elements within the broader socio-
cultural, political and resource contexts of the area(s) in which introduction efforts are 
taking place:  
• the needs of potential users,  
• the services and technologies currently available, and 
• the capability of the service delivery system. 
As highlighted in the US case study, introduction cannot simply consist of making 
the new method available on pharmacy shelves. Instead, it requires the active and 
thoughtful promotion of the product to targeted groups through a variety of strategies 
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and distribution channels including active promotion at those sites, including client 
counseling (UNFPA, WHO & PATH, 2005). Where this is not possible, program 
planners should at the least, “display and distribute educational materials in order to 
give essential information on correct use of the product” (UNFPA, WHO & PATH, 2005, 
p. v).	  	   
In the best case scenario, it includes the support and active leadership of a wide 
range of stakeholders including donor agencies, national governments, community 
leaders, service providers and advocacy groups (Warren & Philpott, 2003). As Warren 
and Philpott (2003, p. 135) note, “NGOs, community-based organizations and especially 
women’s organisations…have been the lead advocates for the establishment of female 
condom programmes. They have mobilised government and donor support to introduce 
the female condom, placed the female condom within the larger context of overall 
community priorities, and promoted increased access to and acceptability of the female 
condom within the community in the context of broader cultural and political issues.” 
Engage communities and advocates 
As stated, fostering a supportive environment is vital for the success of any 
introduction effort (UNFPA, WHO & PATH, 2005).  “People are far more likely to use 
condoms if they perceive that the beliefs and behaviors of their partners, friends, peers 
the immediate community, and broader society favour safer sex practices. Thus, 
condom programming should address the broader community and the political and 
sociocultural environment as well as individual clients” (UNFPA, WHO & PATH, 2005, p. 
61).  
To effectively do this, program planners need to include a wide range of 
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stakeholders including key decision makers, service providers, community leaders and 
relevant advocacy and community-based groups. As UNAIDS and WHO (2005, p. 25) 
point out, “doing this from the outset can help to ensure initial acceptance of the method 
and facilitate the introduction process.” Moreover, involving a wide range of 
stakeholders facilitates general promotion of the product which can, “help to 
destigmatize the method and normalize it as a potential method for all sexually active 
women and men, not just those who engage in high-risk behaviors or are living with HIV 
or AIDS” (Hoffman, 2004, p. 142).   
Carefully select target populations 
According to UNFPA, WHO and PATH (2005, p. 10), “effective ‘programming 
focuses its energy and resources on key client groups’ allowing managers to tailor 
interventions to clients needs, concerns and special circumstances making them more 
likely to increase…[NPT] use and reduce HIV transmission.” As such, before activities 
take place, introduction programs should conduct a comprehensive needs assessment 
that gathers epidemiological, socio-cultural and behavioral information in order to better 
understand potential target groups, their needs, preferences, risk factors and possible 
barriers to use (UNFPA, WHO & PATH, 2005). In this way, social marketing 
campaigns—including branding—and other introduction efforts can be strategically 
tailored to unique target groups, increasing the likelihood that users will adopt the new 
technology.  
Focus on education and training  
In their review of female condom introduction efforts, Frost, Reich and Pratt 
(2008, p. 185) note that, “well designed and implemented training programs and 
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materials can significantly increase adoption.” Comprehensive training and education 
programs include (Frost, Reich & Pratt, 2008; Warren & Philpott, 2003):  
• training for providers to ensure that possible provider biases do not negatively 
influence potential users;  
• training for providers to ensure a client-centered approach where clients 
choose products most appropriate for their personal needs and preferences;   
• training for providers, pharmacists, peer educators and other distributors to 
ensure they can effectively counsel on and demonstrate use of the product, 
teach negotiation and partner communication skills and answer questions 
about sexuality and anatomy;  
• face to face education at distribution sites to equip potential users with 
information and skills; and  
• user-friendly promotion and education materials. 
Training for service providers is a key component of the training and education 
needed for successful introduction. Evidence points not only to the positive role that 
service providers can play in introducing a new prevention technology but that, without 
adequate training, they can actually undermine promotional efforts, effectively 
marginalizing the product (Hoffman, 2004). On the other hand, adequate training and 
education for service providers can help to recruit them as partners in the introduction, 
ensuring they have accurate knowledge, good counseling skills and positive attitudes 
(UNFPA, WHO & PATH, 2005).   
Integrate NPTs into existing health services and programs 
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One key element from the female condom success stories, including South Africa 
and Zimbabwe, was the integration of female condom interventions into existing health 
programs, namely family planning and HIV/AIDS prevention services (Warren & 
Philpott, 2003). Similar integration strategies have also proven effective in introducing 
new contraceptive methods (UNAIDS & WHO, 2005). By integrating introduction efforts 
into established health programs, program planners can capitalize on the success and 
structure of existing services. By introducing products into varied programs, for instance 
family planning, maternal health and HIV prevention programs, planners can expand 
their reach and help to further generalize the technology.  
Ensure strong leadership 
As Frost, Reich & Pratt (2008, p. 185) observed, “a major barrier to female 
condom access has been the absence of an effective global architecture and 
champion.” From ensuring affordable pricing and reliable distribution to developing 
strategic introduction and scale-up programs, leadership—particularly that of donors 
and governments—is crucial for the success of any new prevention technology (Warren 
& Philpott, 2003; UNAIDS & WHO, 2005). Strong leadership is also required to (Frost, 
Reich & Pratt, 2008):  
• develop political and social support; 
• increase public and private sector investment;  
• move beyond the pilot stage to scale up; and   
• to conduct research to improve programming, including operational research 
to identify behavior change strategies and evaluations of long-term impacts. 
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In addition to leadership from governments, donors and the international 
community, female condom programmers have also repeatedly stressed the importance 
of, “cultivating key individuals as advocates…and nearly all mentioned the role of one or 
more charismatic leaders as having been key to…promotion, whether at global, national 
or local levels” (Kaler, 2004b, p. 505). This kind of leadership will prove just as crucial 
for the introduction of NPTs as it was for the female condom.  
Address cost 
In almost all reviews of the female condom, the high cost of the product is cited 
as a major barrier to widespread use and the scaling up of programs (Kaler, 2004b). 
More than twenty years after its initial introduction, the female condom remains an 
expensive commodity compared with the male condom for three main reasons, “the raw 
material is expensive;…the manufacturing technology of female condoms is more 
expensive and complex[than that of the male condom; and]…the overall volume of 
female condoms sold is…[low]” (Warren & Philpott, 2003, p. 136).   
Before NPTs are introduced, and arguably as early as the formulation stage, the 
end cost should be a consideration. Even if a technology were found to be 100 percent 
effective at preventing HIV, if it was unaffordable for the majority of users it would have 
no significant impact in overall HIV rates. From the outset, researchers and other 
stakeholders should ensure the affordability of NPTs by:  
• selecting inexpensive materials, 
• exploring ways to introduce competition into the market, 
• investigating manufacturing capabilities and cost-effectiveness, and 
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• beginning discussions with donor and public health agencies about bulk 
and/or public sector pricing (Frost, Reich & Pratt, 2008). 
Expand distribution systems 
The most successful female condom introduction programs were those that used 
a mix of public and private sector distribution channels, including the use of 
nontraditional channels (such as taxi stations and barber shops) through which to 
promote and distribute the product (Frost, Reich & Pratt, 2008; Warren & Philpott, 
2003). Some of the more traditional distribution channels that proved effective for 
successful female condom programming include, “commercial sales, social marketing, 
community-based distribution, and workplace promotion as well as the health care 
system” (UNFPA, WHO, PATH, 2005, p. 49).  
In order to expand a technology’s use and reach new client groups, program 
planners should employ multiple distribution channels, increase the number and types 
of distribution outlets, and match those outlets to the needs of their target populations 
(UNFPA, WHO & PATH, 2005). In addition, “to ensure a reliable and consistent supply 
of condoms—and thus avoid shortages, stockouts and oversupply—quality monitoring 
must occur at every stage so that all elements of the system operate effectively” 
(UNFPA, WHO, PATH, 2005, p. 33). To this end, program planners should implement 
quality control measures such as a Logistics Management Information System (LMIS) to 
collect and report data about “distribution, monitor stock levels, and make informed 
decisions about product selection, forecasting, procurement, and inventory 
management” (UNFPA, WHO & PATH, 2005, p. 33).  
Engage users’ sexual partners 
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Another major lesson learned from the female condom experience is the 
importance of engaging end users’ sexual partners, in the case of the female condom, 
men. In fact, according to Warren and Philpott (2003, p. 137), while “women have 
typically been the target audience for the promotion of female condoms,…in many 
countries men still maintain the dominant role in sexual decision-making, including 
decisions related to contraception and prevention of STI/HIV. Targeting men in 
promotion and education has proven effective in improving overall acceptability of the 
method.” Involving partners in product promotion can be particularly effective in cultures 
where women have limited power and status (Frost, Reich & Pratt, 2008). Some 
programs have employed the use of trained male health educators to serve as role 
models, reasoning that, “men are more likely to respond to prevention messages if their 
male peers are also doing so” (UNFPA, WHO & PATH, 2005, p. 65).   
As the HIV prevention field begins discussing introduction strategies around a 
range of potential NPTs, how to actively involve the sexual partners of end users will be 
a crucial element.  
Evaluate and redesign programs 
A well developed monitoring and evaluation (M&E) plan, implemented from the 
start, is one of the keys to successfully introducing a NPT. In fact, in terms of female 
condoms, one of the elements that led to success in places like South Africa and 
Zimbabwe was the use of a “long assessment period to gauge performance of the 
distribution programme and to measure use of the female condom over time, not just 
during the novelty stage at programme inception” (Warren & Philpott, 2003, p. 131). 
This kind of M&E plan allows program planners to, “detect and fix problems, assess 
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program performance, and decide which activities to expand or stop” (UNFPA, WHO & 
PATH, 2005). To be effective, M&E systems, “should measure inputs (the number of 
people trained in condom counselling and distribution), outputs (the availability and 
quality of…[the NPT]), outcomes (changes in…[product] use and sexual behaviour) and 
impacts (changes in HIV and STI rates)” (UNFPA, WHO & PATH, 2005, p. v).  
Evaluation efforts should take the long-view, in particular, to account for the time 
needed to demonstrate a meaningful impact. In the case of the female condom, some of 
the evaluation efforts have come under criticism for being too short to effectively 
evaluate the product’s success: 
“Typically, interventions were evaluated after only one to three years. The benefits of 
having female condoms available, however, might take many more years to show up, 
especially when these benefits took the form of broader societal changes in attitudes 
towards sexuality or in women's knowledge of and thus their control over their 
bodies…Positive changes may take decades to show up, as in the case of tampons, for 
example, or the slow uptake of male condoms. Beyond this, they should not look for 
ever-growing numbers of users, instead they should look at the number of potential 
infections averted” (Kaler, 2004, p. 513).   
 
LESSONS THAT NEED TO BE STUDIED FURTHER 
 While the various limiting factors and individual case studies explored in this 
paper offer important lessons for the introduction of future prevention technologies, a 
few key lessons warrant further study.  
• What factors limited the Female Health Company’s ability to effectively 
advertise, promote and increase support of the female condom? 
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• What is the association between availability of national health care and use of 
female condoms? 
•  What is the association between the use of male condoms and use of female 
condoms (i.e., in countries where there is less of a stigma around the use of 
male condoms is there lower use of female condoms due to higher male 
condom use)? 
Exploration of these issues may help to further inform successful introduction strategies 
for new prevention technologies and avoid some of the pitfalls experienced by the 
female condom.  
 
CONCLUSION 
More than twenty years since their initial introduction female condoms remain 
marginalized, suffering from low uptake, high-cost, a lack of recognition and negative 
perceptions. While there are a handful of success stories we can point to, the overall 
experience of female condoms is best described as a missed opportunity for the HIV 
and STI prevention and family planning fields—one that can hopefully be rectified by the 
recent resurgence of advocacy efforts around increasing awareness of and access to 
the product. 
While the case studies of Zimbabwe, South Africa and the US each have unique 
elements, the stories of their successes and failure are characteristic of the range of 
female condom introduction efforts. What’s more, the factors that led to the high uptake 
and sustained use of female condoms in places like South Africa and Zimbabwe, and 
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their marginalization in the US, are directly applicable to the range of NPTs—including 
microbicides, PrEP and vaccines—that are currently in the research pipeline.    
As public health practitioners begin planning for the introduction of this new 
range of HIV prevention technologies, they would do well to examine lessons from the 
female condom experience. Specifically, program planners should take the time to 
thoughtfully and strategically plan and design future introduction programs for NPTs that 
include:  
• engagement with communities and advocates, 
• careful selection of target populations, 
• a focus on education and training, including that of end users’ sexual partners, 
• integration of NPTs into existing health services and programs, 
• strong leadership, 
• negotiations around the end cost of products, 
• varied distribution systems, and  
• ongoing efforts to monitor and evaluate programs, with a commitment to 
redesigning them when necessary.  
While further examination of some key issues is needed, the lessons outlined 
here provide a base of knowledge the public health field can use to implement 
informed introduction efforts in order to better guarantee the ability of NPTs to 
increase protection and reduce the overall incidence of HIV.  
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